Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch from lopinavir/ritonavir to atazanavir/ritonavir or nevirapine with abacavir/lamivudine in virologically suppressed HIV patients
2006-006716-30Phase 4Completed
- Sponsor
- Sant'Orsola-Malpighi University Hospital
- Start
- Feb 2007
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of atazanavir, nevirapine, lopinavir, ritonavir, abacavir and 1 more in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Sant'Orsola-Malpighi University Hospital. Primary endpoint: Virologic suppression at 12 months. Started Feb 2007; status: completed.
02
Drugs
atazanavirnevirapinelopinavirritonavirabacavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2006-006716-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006716-30.